Last reviewed · How we verify
Intravitreal Aflibercept Injection 2mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravitreal Aflibercept Injection 2mg (Intravitreal Aflibercept Injection 2mg) — Tennessee Retina.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravitreal Aflibercept Injection 2mg TARGET | Intravitreal Aflibercept Injection 2mg | Tennessee Retina | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravitreal Aflibercept Injection 2mg CI watch — RSS
- Intravitreal Aflibercept Injection 2mg CI watch — Atom
- Intravitreal Aflibercept Injection 2mg CI watch — JSON
- Intravitreal Aflibercept Injection 2mg alone — RSS
Cite this brief
Drug Landscape (2026). Intravitreal Aflibercept Injection 2mg — Competitive Intelligence Brief. https://druglandscape.com/ci/intravitreal-aflibercept-injection-2mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab